PF329

PF329 is an extended-release prodrug of hydromorphone developed to provide pain relief with inherent abuse-deterrent properties. It utilizes Ensysce Biosciences' proprietary BIO-MD™ and MPAR™ (Multi-Pill Abuse Resistance) technologies, which are designed to make the drug pharmacologically inactive until activated by specific enzymes in the gastrointestinal tract, thereby reducing the risk of abuse via non-oral routes. The prodrug is intended for oral administration and aims to improve patient care in severe pain management while minimizing risks associated with opioid misuse. Clinical studies have evaluated its safety and pharmacokinetics compared to standard hydromorphone formulations[1][2][3][9].